A Review of new atypical antipsychotic launches in the United States

Psychiatry (Edgemont)

Volumn 7, Issue 12, 2010, Pages 13-15

  Ventimiglia, Jeff ^a   Kalali, Amir H ^b   Citrome, Leslie ^c  

^a IQVIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

Antipsychotic; Asenapine; Atypical; Bipolar disorder; Fanapt; Iloperidone; Product launches; Saphris; Schizophrenia

Indexed keywords

ASENAPINE; DOPAMINE 2 RECEPTOR; ILOPERIDONE; LURASIDONE; SEROTONIN 2A RECEPTOR; ZIPRASIDONE;

AKATHISIA; ARTICLE; BIPOLAR MANIA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; GENETIC HETEROGENEITY; HUMAN; MIXED MANIA AND DEPRESSION; ORTHOSTATIC HYPOTENSION; PRESCRIPTION; QT PROLONGATION; SCHIZOPHRENIA; UNITED STATES;

EID: 79951563077     PISSN: 15505952     EISSN: 15555194     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed secondgeneration antipsychotic. Int J Clin Pract. 2009;63(12):1762-1784.
2. Citrome L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010;6(12):1551-1564
3. Citrome L. Iloperidone redux: a dissection of the drug approval package for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2010;64(6):707-718
4. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised secondgeneration antipsychotic. Int J Clin Pract. 2009;63(8):1237-1248.
5. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10(12):1917-1928.
6. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. (In press) Available on-line early at doi: 10.1111/j.1742-1241.2010.02587.x